A Phase IIb Study of ABT‐494, a Selective JAK‐1 Inhibitor, in Patients With Rheumatoid Arthritis and an Inadequate Response to Anti–Tumor Necrosis Factor Therapy

Eitemau Tebyg

• Efficacy and Safety of ABT‐494, a Selective JAK‐1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate
  gan: Genovese, Mark C., et al.
  Cyhoeddwyd: (2016)
• In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494)
  gan: Parmentier, Julie M., et al.
  Cyhoeddwyd: (2018)
• ABT‐122, a Bispecific Dual Variable Domain Immunoglobulin Targeting Tumor Necrosis Factor and Interleukin‐17A, in Patients With Rheumatoid Arthritis With an Inadequate Response to Methotrexate: A Randomized, Double‐Blind Study
  gan: Genovese, Mark C., et al.
  Cyhoeddwyd: (2018)
• Phase II Study of ABT‐122, a Tumor Necrosis Factor– and Interleukin‐17A–Targeted Dual Variable Domain Immunoglobulin, in Patients With Psoriatic Arthritis With an Inadequate Response to Methotrexate
  gan: Mease, Philip J., et al.
  Cyhoeddwyd: (2018)
• Sarilumab improves patient-reported outcomes in rheumatoid arthritis patients with inadequate response/intolerance to tumour necrosis factor inhibitors
  gan: Strand, Vibeke, et al.
  Cyhoeddwyd: (2017)